Description

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer[1][2].–80°C, protect from light-Applications–Formula-N/A-Citation–References-[1]Menderes G, et, al. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecol Oncol. 2017 Oct;147(1):145-152.|[2]Verma S, et, al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov 8;367(19):1783-91.-CASNumber-1018448-65-1-MolecularWeight-N/A-Compound Purity-99.01-SMILES-[Trastuzumab emtansine (solution)]-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-Antibody-Drug Conjugates (ADCs);EGFR-Isoform–Pathway-Antibody-drug Conjugate/ADC Related;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK-MCE Product type-ADC Related